BACKGROUND:: The results of the INFORM study (NCT00770588; C-TONG 0804), which compared @entity4562 and placebo as maintenance therapy in @entity1 with advanced @entity1149 ( @entity1149 ) without disease progression after first-line chemotherapy, were published previously. The objective of this report is to provide a mature analysis of @entity3012 for INFORM study in ITT population and in subgroups according to @entity470 ( @entity470 ) mutation status. @entity1 AND METHODS:: A total of 296 @entity1 were randomly assigned. @entity470 mutations were detected using an amplification mutation refractory system (ARMS). Seventy nine @entity1 were assessable for @entity470 mutations. Overall survival was analysed by a Cox proportional hazards model adjusted for the same covariates in intention to treat (ITT) population and subgroups according to @entity470 mutation status. RESULTS:: Overall survival was similar for @entity4562 and placebo arm with no significant difference between treatments in ITT population (HR, 0.88; 95% CI, 0.68 to 1.14; P=0.335), and in subgroups with wild type @entity470 (HR 1.27; 95% CI 0.7 to 2.3; P=0.431) or unknown @entity470 mutations (HR 0.92; 95% CI 0.68, 1.25; P=0.603). In the @entity470 mutation-positive subgroup, the @entity4562 arm showed a higher @entity3012 than the placebo arm (HR 0.39; 95% CI 0.15, 0.97; P=0.036). CONCLUSION:: @entity470 mutation was the strongest predictive biomarker for @entity3012 benefit of @entity4562 as maintenance treatment. The analyses of @entity3012 showed that @entity1 achieve a clear and significant survival benefit if they receive @entity470 TKIs as maintenance treatment in @entity470 mutation positive @entity1 .

Final overall survival results from a phase III, randomised, placebo-controlled, parallel-group study of @entity4562 versus placebo as maintenance therapy in @entity1 with locally advanced or metastatic XXXX (INFORM; C-TONG 0804).

@entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS'] @entity4562 :: ('MESH:C419708', 'Chemical') :: ['gefitinib'] @entity3012 :: ('MESH:C567932', 'Disease') :: ['OS'] @entity470 :: ('1956', 'Gene') :: ['EGFR', 'epidermal growth factor receptor'] @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC', 'non-small-cell lung cancer']
@entity1149 :: (MESH:D002289,Disease) :: ['non-small-cell lung cancer']
